Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - Deferred ChargesLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

BioXcel Therapeutics (BTAI) Leases (2022 - 2025)

BioXcel Therapeutics has reported Leases over the past 4 years, most recently at $56000.0 for Q4 2025.

  • Quarterly results put Leases at $56000.0 for Q4 2025, down 85.34% from a year ago — trailing twelve months through Dec 2025 was $56000.0 (down 85.34% YoY), and the annual figure for FY2025 was $56000.0, down 85.34%.
  • Leases for Q4 2025 was $56000.0 at BioXcel Therapeutics, down from $140000.0 in the prior quarter.
  • Over the last five years, Leases for BTAI hit a ceiling of $1.2 million in Q1 2022 and a floor of $56000.0 in Q4 2025.
  • Median Leases over the past 4 years was $650500.0 (2023), compared with a mean of $638812.5.
  • Biggest five-year swings in Leases: decreased 23.29% in 2023 and later tumbled 85.34% in 2025.
  • BioXcel Therapeutics' Leases stood at $976000.0 in 2022, then dropped by 29.51% to $688000.0 in 2023, then crashed by 44.48% to $382000.0 in 2024, then tumbled by 85.34% to $56000.0 in 2025.
  • The last three reported values for Leases were $56000.0 (Q4 2025), $140000.0 (Q3 2025), and $222000.0 (Q2 2025) per Business Quant data.